Lakefront Biotherapeutics | GLPG - Selling And Administration Expenses


Lakefront Biotherapeutics reported EUR35.5M in Selling and Administration Expenses for its fiscal quarter ending in March of 2026.





Selling And Administration Expenses Change Date
argenx SE USD 417M 62M Jun/2026
AstraZeneca USD 5.8B 735M Jun/2026
Biogen USD 709.7M 155.4M Jun/2026
Genmab DKK 208M 60M Dec/2025
Gilead Sciences USD 1.45B 326M Mar/2026
GlaxoSmithKline GBP 2.19B 75M Jun/2026
GRIFOLS EUR 289M 8M Jun/2026
Hikma Pharmaceutical USD 288M 149M Dec/2025
Incyte USD 351.73M 23.64M Jun/2026
Merck EUR 1.52B 80M Mar/2026
Neurocrine Biosciences USD 383.1M 64.6M Jun/2026
Novartis USD 3.24B 101M Jun/2026
Roche Holding CHF 6.37B 908M Jun/2026
Sanofi EUR 2.63B 307M Jun/2026
UCB EUR 1.47B 193M Dec/2025
Vertex Pharmaceuticals USD 582.2M 88.5M Jun/2026